BioStem Technologies (BSEM) has seen its stock move sharply in recent trading, with a 17.6% one-day return and gains over the past week, month, and past three months drawing fresh investor attention.

BioStem Technologies is a buy due to strong YoY growth, profitability, and undervaluation versus sector peers despite recent Q1 misses. Their advanced wound care products, powered by proprietary ...

$BSEM ($BSEM) is expected to release its quarterly earnings data on Monday, April 7th after market close, per Finnhub. Analysts are expecting revenue of $88,418,700 ...

BioStem Technologies Inc. Annual cash flow by MarketWatch. View BSEM net cash flow, operating cash flow, operating expenses and cash dividends.

Ladies and gentlemen, good afternoon. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioStem Technologies' fourth-quarter and ...

Short interest in BioStem Technologies Inc (OTC:BSEM) increased during the last reporting period, rising from 137.80K to 191.18K. This put -% of the company's publicly available shares short. Short ...

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial performance of ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. With no fresh headline event driving attention to BioStem Technologies (BSEM), recent ...

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. It offers pre-treatment assessment, cell therapies, anti-aging, and wellness compounds. The ...